IPG PHOTONICS ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS
IPG PHOTONICS CORP (IPGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IPG PHOTONICS ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Double-Digit Revenue Growth Driven by Strategic Initiatives Across Industrial and Advanced Solutions Focused on Driving Margin Expansion MARLBOROUGH, Mass. – November 3, 2026 - IPG Photonics Corporation (NA
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance upgrade provide a fresh catalyst for the stock, likely prompting short‑term buying.
Market read
The earnings release adds new material information for traders, with clear upside potential for IPGP.
What to watch
Potential tariff refunds and foreign exchange effects could moderate margin improvements.
Double-Digit Revenue Growth Driven by Strategic Initiatives Across Industrial and Advanced Solutions Focused on Driving Margin Expansion
Third-quarter revenue increased 15%, with 12% Industrial Solutions growth and 33% Advanced Solutions growth. GAAP gross margin increased to 40.7%, while GAAP operating income rose to $20.8 million from $7.9 million and adjusted EBITDA rose 39% to $51.5 million. Fourth-quarter revenue guidance is $265 million to $295 million, with tariff and trade-policy uncertainty identified as risks.
Actuals vs. the company’s prior outlook
from its previous release| Metric | Guided | Reported | Verdict |
|---|---|---|---|
| Revenue, Q3 2026 | $265 million to $295 million | $ 287.5 million | in line |
| Non-GAAP adjusted gross margin, Q3 2026 | between 37.5% and 40.5% | 41.0 % | above |
| Non-GAAP adjusted operating expenses, Q3 2026 | $92 million to $95 million | $ 91,240 (in thousands) | below |
| Non-GAAP adjusted earnings per diluted share, Q3 2026 | $0.30 to $0.60 | $ 0.61 | above |
| Non-GAAP adjusted EBITDA, Q3 2026 | $35 million to $51 million | $ 51.5 million | above |
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, three months ended September 30, 2026GAAP | $287.5M | – | 15 % |
| Gross margin, three months ended September 30, 2026GAAP | 40.7 % | – | – |
| Gross profit, three months ended September 30, 2026GAAP | $117.1M | – | – |
| Operating income, three months ended September 30, 2026GAAP | $20.8M | – | NM |
| Operating margin, three months ended September 30, 2026GAAP | 7.2 % | – | – |
| Net income, three months ended September 30, 2026GAAP | $20.3M | – | 171 % |
| Earnings per diluted share, three months ended September 30, 2026GAAP | $ 0.47 | – | 161 % |
| Adjusted gross margin, three months ended September 30, 2026non-GAAP | 41.0 % | – | – |
| Adjusted operating expenses, three months ended September 30, 2026non-GAAP | $91.24M | – | – |
| Adjusted operating income, three months ended September 30, 2026non-GAAP | $26.53M | – | – |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | $51.5M | – | 39 % |
| Adjusted net income, three months ended September 30, 2026non-GAAP | $26.27M | – | – |
| Adjusted earnings per diluted share, three months ended September 30, 2026non-GAAP | $ 0.61 | – | 74 % |
| Tax rate, three months ended September 30, 2026GAAP | 29 % | – | – |
| Adjusted tax rate, three months ended September 30, 2026non-GAAP | 23 % | – | – |
| Revenue, nine months ended September 30, 2026GAAP | $831.6M | – | 14 % |
| Gross margin, nine months ended September 30, 2026GAAP | 39.6 % | – | – |
| Gross profit, nine months ended September 30, 2026GAAP | $329.1M | – | – |
| Operating income, nine months ended September 30, 2026GAAP | $17.6M | – | NM |
| Operating margin, nine months ended September 30, 2026GAAP | 2.1 % | – | – |
| Net income, nine months ended September 30, 2026GAAP | $27.1M | – | 52 % |
| Earnings per diluted share, nine months ended September 30, 2026GAAP | $ 0.63 | – | 50 % |
| Adjusted gross margin, nine months ended September 30, 2026non-GAAP | 39.9 % | – | – |
| Adjusted operating expenses, nine months ended September 30, 2026non-GAAP | $271.8M | – | – |
| Adjusted operating income, nine months ended September 30, 2026non-GAAP | $59.65M | – | – |
| Adjusted EBITDA, nine months ended September 30, 2026non-GAAP | $135.2M | – | 34 % |
| Adjusted net income, nine months ended September 30, 2026non-GAAP | $63.93M | – | – |
| Adjusted earnings per diluted share, nine months ended September 30, 2026non-GAAP | $ 1.49 | – | 55 % |
| Tax rate, nine months ended September 30, 2026GAAP | 35 % | – | – |
| Adjusted tax rate, nine months ended September 30, 2026non-GAAP | 24 % | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Industrial Solutions, three months ended September 30, 2026Strong performance in welding and additive manufacturing applications. | $239.5M | – | 12 % |
| Advanced Solutions, three months ended September 30, 2026Higher sales in semiconductor and defense applications. | 47.95M | – | 33 % |
| Industrial Solutions, nine months ended September 30, 2026Driver for the nine-month period was not separately provided. | $704.2M | – | 16 % |
| Advanced Solutions, nine months ended September 30, 2026Driver for the nine-month period was not separately provided. | 127.4M | – | 5 % |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
fourth quarter of 2026 outlook
- Revenue$265 million to $295 million
- Gross margin37.0% and 40.0%
- Operating expenses$91 million to $94 million
- NoteAdjusted earnings per diluted share in the range of $0.30 to $0.60
- NoteAdjusted EBITDA in the range of $33 million to $50 million
- NoteGuidance assumes no contribution from the acquisition of Lumibird Medical.
- NoteGuidance assumes exchange rates relative to the U.S. dollar of euro 0.88, Japanese yen 157 and Chinese yuan 6.74, respectively.
Capital returns
- Purchase of treasury stock net of excise tax, at cost: $ 2,648 (in thousands) for the nine months ended September 30, 2026, compared with $ 46,603 (in thousands) for the nine months ended September 30, 2025.
- Payments for taxes related to net share settlement of equity awards less proceeds from issuance of common stock under employee stock option and purchase plans: $ 11,053 (in thousands) for the nine months ended September 30, 2026, compared with $ 4,316 (in thousands) for the nine months ended September 30, 2025.
What drove it
- Third-quarter revenue increased 15% year over year, driven by 12% growth in Industrial Solutions and 33% growth in Advanced Solutions.
- Changes in foreign exchange rates increased revenue by approximately 1%.
- Industrial Solutions sales accounted for 83% of total revenue.
- Emerging growth products accounted for 52% of total revenue, down from 58% in the prior quarter due to product mix.
- By region, sales increased 14% in Asia and 33% in North America and decreased 1% in Europe on a year-over-year basis.
- GAAP gross margin of 40.7% and adjusted gross margin of 41.0% increased year over year, driven by lower product costs and $5.0 million in net tariff refunds recorded in the period, partially offset by lower fixed cost absorption.
- Third-quarter book-to-bill was approximately one.
Concerns
- Lower fixed cost absorption partially offset the gross-margin benefit from lower product costs and $5.0 million in net tariff refunds.
- Emerging growth products accounted for 52% of total revenue, down from 58% in the prior quarter due to product mix.
- Europe sales decreased 1% on a year-over-year basis.
- The current uncertainty related to the trade environment and tariff policies increases the risks to the outlook provided.
- The filing identifies product demand, order cancellations and delays, competition, tariffs and retaliatory tariffs, currency fluctuations and general economic conditions as factors that may cause actual results to differ from guidance.
What to watch
- Fourth-quarter revenue delivery against the $265 million to $295 million outlook.
- Fourth-quarter adjusted gross margin against guidance of 37.0% and 40.0%.
- Fourth-quarter adjusted operating expenses against guidance of $91 million to $94 million.
- Fourth-quarter adjusted earnings per diluted share outlook of $0.30 to $0.60 and adjusted EBITDA outlook of $33 million to $50 million.
- The expected closing of the Lumibird Medical acquisition in the fourth quarter and its expected future impact on Advanced Solutions, noting that fourth-quarter guidance assumes no contribution from the acquisition.
- Industrial demand and adoption of welding, additive manufacturing, semiconductor and defense solutions.
- Trade policy changes, trade restrictions, tariffs and currency conditions.
Balance sheet and cash flow
- Cash and cash equivalents: $ 710,688 (in thousands) at September 30, 2026, compared with $ 403,790 (in thousands) at December 31, 2025.
- Short-term investments: $ 215,304 (in thousands) at September 30, 2026, compared with $ 435,538 (in thousands) at December 31, 2025.
- Long-term investments: — at September 30, 2026, compared with $ 76,533 (in thousands) at December 31, 2025.
- Inventories: $ 337,890 (in thousands) at September 30, 2026, compared with $ 313,416 (in thousands) at December 31, 2025.
- Accounts receivable, net: $ 191,150 (in thousands) at September 30, 2026, compared with $ 181,734 (in thousands) at December 31, 2025.
- Property, plant and equipment, net: $ 648,326 (in thousands) at September 30, 2026, compared with $ 637,516 (in thousands) at December 31, 2025.
- Total assets: $ 2,472,043 (in thousands) at September 30, 2026, compared with $ 2,424,280 (in thousands) at December 31, 2025.
- Total liabilities: $ 317,095 (in thousands) at September 30, 2026, compared with $ 296,150 (in thousands) at December 31, 2025.
- Total stockholders' equity: $ 2,154,948 (in thousands) at September 30, 2026, compared with $ 2,128,130 (in thousands) at December 31, 2025.
- Net cash provided by operating activities: $ 78,531 (in thousands) for the nine months ended September 30, 2026, compared with $ 46,535 (in thousands) for the nine months ended September 30, 2025.
- During the third quarter, IPG generated $46 million in cash flow from operations and spent $17 million on capital expenditures.
- Purchases of and deposits on property, plant and equipment: $ 54,437 (in thousands) for the nine months ended September 30, 2026, compared with $ 60,907 (in thousands) for the nine months ended September 30, 2025.
- Net cash provided by investing activities: $ 244,270 (in thousands) for the nine months ended September 30, 2026, compared with net cash used in investing activities of $ 292,904 (in thousands) for the nine months ended September 30, 2025.
- Net cash used in financing activities: $ 13,701 (in thousands) for the nine months ended September 30, 2026, compared with $ 50,919 (in thousands) for the nine months ended September 30, 2025.
- Cash, cash equivalents and cash held for sale — End of period: $ 711,163 (in thousands) at September 30, 2026, compared with $ 346,026 (in thousands) at September 30, 2025.
Analysis
IPG reported third-quarter revenue of $287.5 million, up 15% from $250.8 million. Growth was broad across its two reported applications: Industrial Solutions rose 12% to $239,548 and Advanced Solutions rose 33% to 47,952. Industrial Solutions represented 83% of total revenue, supported by welding and additive manufacturing, while Advanced Solutions benefited from semiconductor and defense sales. Foreign exchange rates increased revenue by approximately 1%. Regional performance was led by North America, up 33%, and Asia, up 14%, while Europe declined 1%.
Profitability improved substantially. GAAP gross margin was 40.7%, compared with 39.5%, and adjusted gross margin was 41.0%, compared with 39.8%. Management cited lower product costs and $5.0 million in net tariff refunds, partly offset by lower fixed cost absorption. GAAP operating income was $20.8 million versus $7.9 million, and net income was $20.3 million versus $7.5 million. Diluted EPS was $0.47, compared with $0.18. Adjusted EBITDA increased 39% to $51.5 million and adjusted diluted EPS increased 74% to $0.61.
Nine-month revenue was $831.6 million, up 14%, while GAAP operating income was $17.6 million and net income was $27.1 million. The nine-month operating results include $17,805 (in thousands) of impairment charges and $14,435 (in thousands) of settlement and fees of litigation matters within the non-GAAP reconciliation. Cash generation improved, with nine-month net cash provided by operating activities of $78,531 (in thousands), compared with $46,535 (in thousands). Cash and cash equivalents were $710,688 (in thousands) at September 30, 2026, and short-term investments were $215,304 (in thousands).
Product mix remains important. Emerging growth products were 52% of total revenue, down from 58% in the prior quarter due to product mix. The company described third-quarter book-to-bill as approximately one, alongside improved industrial demand. It also expects the Lumibird Medical acquisition to close in the fourth quarter, but fourth-quarter guidance assumes no contribution from that acquisition.
For the fourth quarter, IPG guides for revenue of $265 million to $295 million, adjusted gross margin between 37.0% and 40.0%, adjusted operating expenses of $91 million to $94 million, adjusted EPS of $0.30 to $0.60, and adjusted EBITDA of $33 million to $50 million. Management specifically highlighted current uncertainty related to the trade environment and tariff policies as increasing the risks to this outlook. The principal reported operating watchpoints are the guide range, gross-margin sensitivity to fixed-cost absorption and tariff effects, regional trends including Europe, and sustained execution in industrial, semiconductor and defense markets.
Management, verbatim
We delivered our fourth consecutive quarter of double-digit year-over-year revenue growth, with revenue above the midpoint of our guidance.
Dr. Mark Gitin, Chief Executive Officer of IPG Photonics
Our performance reflects the strength of our technology, disciplined execution, and continued progress in expanding our presence in attractive, higher-growth markets.
Dr. Mark Gitin, Chief Executive Officer of IPG Photonics
Our third quarter book-to-bill was approximately one as we continued to see improved industrial demand and executed on our strategic growth initiatives, driving adoption for our differentiated laser and photonics solutions that deliver measurable value to customers.
Dr. Mark Gitin
Not in the filing
stated, not guessed- Free cash flow was not reported.
- Debt was not separately reported.
- Third-quarter detailed cash-flow statement line items were not reported; only third-quarter cash flow from operations of $46 million and capital expenditures of $17 million were disclosed.
- Prior-quarter values were not reported for revenue, margins, operating income, net income, EPS, adjusted EBITDA, or the reported segments.
- A fourth-quarter tax-rate guidance figure was not reported.
- Dividend information was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
IPG Photonics filed a Form 8‑K reporting its Q3 2026 earnings and forward outlook, including an upcoming acquisition.
Ticker impact
IPG Photonics reported Q3 2026 results with 15% revenue growth and issued guidance for Q4 revenue $265M-$295M.
likely upward pressure as investors price in higher revenue and margin expansion
Revenue beat prior year, margins improved, and guidance tops prior expectations, supporting a bullish outlook.
Market effects
Laser and photonics sector may see increased investor interest from strong industrial and advanced solutions demand.
North America sales growth could boost regional tech exposure, while Europe slight decline may temper local sentiment.
Guidance and acquisition news may influence global industrial equipment and defense supply chains.
Counterpoint
If the upcoming Lumibird Medical acquisition faces integration delays, the guidance could be overly optimistic.
Key entities
- companyIPG Photonics Corp
Laser and photonics solutions provider.
- companyLumibird Medical
Target acquisition to expand medical market presence.




